About 90% of medullary thyroid carcinomas (MTCs) express the transmembrane G protein–coupled cholecystokinin 2 receptor (CCK2R) at a high density [1], making CCK2R an interesting target for peptide receptor radionuclide therapy (PRRT). The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.